Neurocrine to Acquire Soleno Therapeutics for $2.9 Billion

Neurocrine Biosciences is set to acquire Soleno Therapeutics in a cash deal valued at $2.9 billion. This strategic acquisition aims to expand Neurocrine's portfolio in endocrinology and rare disease treatments. Soleno Therapeutics brings a key drug for hyperphagia associated with Prader-Willi syndrome, offering a significant therapeutic advancement. The deal highlights Neurocrine's commitment to growing its presence in specialized pharmaceutical markets and addressing critical patient needs.